Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

Refeyn, the company behind pioneering mass photometry technologies, has developed and launched a custom software platform ...

Proteins are essential components of cellular life, uniquely translating genetic information into a vast array of molecular ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

FDA IND approval for TB006 is a major achievement for TrueBinding and a significant potential advancement for the treatment of Parkinson’s Disease worldwide,” said Alan K. Jacobs, M.D., FAAN, Chief ...

Treatment with Vaccinex's pepinemab antibody to SEMA4D slowed expression of key biomarkers of disease progression ... the Company entered into a securities purchase agreement pursuant to which the ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Surrozen (SRZN) announced a strategic research collaboration with privately-held TCGFB to discover antibody therapeutics targeting Transforming ...

Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-ß product related intellectual property. In exchange for ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...